QX027N is a long-acting anti-TSLP×IL-13 bispecific antibody, in development for the treatment of atopic dermatitis (AD) and asthma. It has received the Clinical  Trial Implicit Permission for clinical trials from the Center for Drug Evaluation of the National Medical Products Administration (Acceptance Nos.: CXSL2500757, CXSL2500758). On December 12, 2025, Qyuns successfully initiated the Phase I clinical trial for QX027N by enrolling the first subject in China. The Phase II clinical trial is expected to be launched in H2 2026.

In December 2025, Qyuns entered into a license and collaboration agreement with LE2025 Therapeutics AG ("LE2025"), an affiliate of Windward Bio Group. According to the agreement, LE2025 is granted an exclusive license to develop and commercialize QX027N globally, except from mainland China, Taiwan, the Special Administrative Region of Hong Kong and the Special Administrative Region of Macau (the “Licensed Territory”).In return, Qyuns will be entitled to receive a total of up to USD$700 million payments, including an upfront payment, an equity interest of Windward Bio, development and commercial milestone payments, plus tiered royalties on net sales of QX027N in the Licensed Territory.